Omeros (NASDAQ:OMER) Share Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Omeros Corporation (NASDAQ:OMER – Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $13.80 and traded as low as $13.07. Omeros shares last traded at $13.21, with a volume of 2,019,480 shares trading hands.

Key Headlines Impacting Omeros

Here are a few of the latest headlines about OMER:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $33 price target, raising its FY2026 EPS estimate to a loss of $0.08 per share from a loss of $0.37, and increasing its FY2029 and FY2030 forecasts. Analyst forecasts for Omeros
  • Positive Sentiment: Cantor Fitzgerald reiterated a Buy rating, adding to the positive analyst commentary. Cantor Fitzgerald remains a Buy
  • Positive Sentiment: An earnings-call report highlighted growth for YARTEMLEA, which may support investor optimism about the product’s commercial prospects. Omeros earnings call highlights YARTEMLEA growth

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price target on shares of Omeros in a research report on Tuesday, November 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $22.00 price objective on shares of Omeros in a research note on Wednesday, October 14th. Weiss Ratings lowered shares of Omeros from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday. Finally, Wall Street Zen cut Omeros from a “buy” rating to a “hold” rating in a report on Saturday. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $30.33.

Get Our Latest Stock Report on Omeros

Omeros Trading Down 5.7%

The company’s 50 day moving average is $17.83 and its 200 day moving average is $13.80. The company has a market cap of $956.25 million, a PE ratio of 13.76 and a beta of 2.96.

Omeros (NASDAQ:OMER – Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.04. The firm had revenue of $35.93 million during the quarter, compared to analysts’ expectations of $37.28 million. Analysts expect that Omeros Corporation will post -0.08 EPS for the current year.

Insider Buying and Selling at Omeros

In other Omeros news, VP Peter Cancelmo sold 25,000 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the sale, the vice president directly owned 200 shares in the company, valued at approximately $3,708. This represents a 99.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Arnold Hanish sold 10,000 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the transaction, the director directly owned 5,000 shares in the company, valued at $94,750. The trade was a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 75,906 shares of company stock valued at $1,438,705 in the last ninety days. Corporate insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On Omeros

A number of hedge funds and other institutional investors have recently bought and sold shares of OMER. China Universal Asset Management Co. Ltd. grew its stake in Omeros by 3.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 15,708 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 589 shares during the last quarter. Sterling Capital Management LLC raised its stake in Omeros by 75.3% in the third quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 758 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in Omeros by 13.6% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 17,500 shares of the biopharmaceutical company’s stock worth $333,000 after acquiring an additional 2,100 shares in the last quarter. Brighton Jones LLC boosted its holdings in Omeros by 9.9% in the third quarter. Brighton Jones LLC now owns 34,739 shares of the biopharmaceutical company’s stock worth $661,000 after acquiring an additional 3,142 shares in the last quarter. Finally, GK Wealth Management LLC purchased a new stake in shares of Omeros during the third quarter worth about $65,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

(Get Free Report)

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

Further Reading

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.